Anthem Biosciences Ltd

- The transcript provided does not mention any current or future plans for fundraising through debt or equity by Anthem Biosciences Limited. - There is no discussion about issuing new shares, raising capital, or taking on additional debt in the Q3 & 9M FY26 earnings call. - The focus is primarily on organic growth through investments in technology, capacity expansion (e.g., Unit-4 CAPEX), and operational performance. - Management emphasizes strong financial health with growing EBITDA and PAT margins, but no specific fundraising plans are disclosed. - Any future fundraising, if planned, was not communicated in the available excerpts from the February 2026 earnings call.

- Unit-4 Expansion: Rs. 1,000 crore CAPEX planned over two years for Unit-4 on a 30-acre land parcel; currently in early stage with ongoing civil work. Major CAPEX spend expected in FY27. - New Capacity for Biosimilars: A separate new facility planned for CHO cell-based mammalian biosimilars beyond current 200-liter capacity. - 16 KL Peptide Facility: Replacement cost estimated at about Rs. 200 crore including utilities; already commissioned a state-of-the-art 16 KL commercial peptide manufacturing facility. - Capacity Planning: Expansion is done proactively based on pipeline progress to attract and handle more projects; focus on Greenfield builds to meet high regulatory and customer standards. - Backward Integration: Completed discontinuation of China-sourced intermediates, now fully backward integrated, contributing to margin improvements and strategic self-reliance.

- Anthem expects steady progress in revenue with a mid-teens growth (around 15%-16%) for FY26, despite a high base last year. - Improvement anticipated in FY27 and FY28, with optimism about returning to approximately 20% growth CAGR over the next five years. - Growth drivers include ramp-up of recently commercialized products, existing commercial products expanding market share, new large pharma customers, and increased demand post-destocking. - Pipeline is robust with 130-140 early-stage molecules and 6 in Phase-2 likely to move to Phase-3 in 18-30 months. - Positive outlook on biotech sector tailwinds due to government encouragement and trade deals. - GLP-1 peptides expected to become significant contributors, though not exceeding 20%-30% of turnover. - Specialty ingredients growth driven by GLP-1, probiotics, and biosimilars. - Margin improvements expected to sustain due to backward integration and operating leverage.

- Anthem Biosciences expects steady topline and bottom-line growth with potential to sustain a CAGR similar to the last five years over the next few years. - FY27 growth visibility is positive but uncertain; management is optimistic but cautious due to market lumpiness. - Q4 FY26 typically strongest quarter; full-year revenue growth expected around mid-teens (15-16%). - EBITDA margin trending north with aspirations to maintain or improve above 40%; full-year FY26 EBITDA growth guidance is 20%+. - PAT margin expected to remain strong, with 20%+ growth guidance for FY26. - Growth drivers include ramp-up of recently commercialized products, expansion in specialty ingredients (GLP-1, probiotics, biosimilars), and increased capacity (Unit-4 CAPEX underway). - Destocking pressures affecting recent quarters expected to normalize, leading to stronger demand in coming years. - Currency appreciation benefits recognized as other income supporting margins. - Overall outlook remains positive given regulatory, trade improvements, and expanded customer base.

- Anthem Biosciences currently has a robust order book with around 130 to 140 early-stage pipeline molecules. - Approximately 5 to 6 molecules are in Phase 2, expected to move to Phase 3 within 18 to 30 months, subject to clinical outcomes. - Six molecules remain in Phase 3, with 4 recently commercialized. - The company has added multiple large pharma customers this year, including supply of advanced intermediates and development work for approved products. - There has been an increase in requests for RFQs (Request for Quotations) in recent quarters, indicating growing demand. - Anthem is seeing signs of recovery post-destocking by customers, which had temporarily softened performance. - The management anticipates continued strong order inflow and a positive outlook, supported by new product launches and expansion in biotech and specialty ingredients segments.